Business Wire

Cirium Enhances Industry-Leading On-Time Performance Advisory Board with Three Esteemed Aviation Leaders

4.12.2024 12:12:00 CET | Business Wire | Press release

Share

Cirium, the world’s most trusted source of aviation analytics, has appointed three prominent aviation experts to its Airline and Airport On-Time Performance Advisory Board. The move underscores Cirium’s commitment to maintaining its position as the global gold standard for airline and airport performance analytics.

As the first and only company to establish an On-Time Performance Advisory Board, Cirium ensures an unbiased, data-driven view of operational excellence. The latest appointments—Eamonn Brennan, Scott McCartney, and Alex de Gunten—bring over 75 years of combined experience, enhancing the board’s mission to uphold Cirium’s reputation as the industry benchmark.

Jeremy Bowen, Cirium CEO, said “Adding Eamonn, Scott, and Alex to our Advisory Board is a confirmation of our unwavering commitment to operational reliability and excellence. Their unique perspectives, spanning safety, operations, performance, journalism, and global airline strategy, will amplify our ability to provide independent, accurate data and insights. Together, we are shaping the future of aviation performance analytics for our partners worldwide.”

Meet the New Advisory Board Members

Eamonn Brennan

Eamonn Brennan joins the board with a distinguished record of leadership in aviation safety, performance, and airspace management. Currently serving as a Non-Executive Director at Ryanair, Brennan was the Director General of EUROCONTROL from 2018 to 2022, steering the organization through pivotal challenges such as the record-setting summer of 2019 and the COVID-19 pandemic. During his tenure, he ensured the resilience of the European Air Traffic Network, overseeing 11 million annual flights.

Previously, Brennan served as Chief Executive of the Irish Aviation Authority (2002–2017), achieving significant advancements in safety, cost efficiency, and airspace management. A pioneer in privatization efforts, he led the Airline Group’s successful bid for the UK’s first partial privatization of an Air Navigation Service Provider. Brennan has also held key leadership roles, including Chairman of CANSO Global and the COOPANS Alliance.

Scott McCartney

Scott McCartney, a renowned aviation journalist and business consultant, brings decades of expertise in analyzing and reporting on industry trends. For over 20 years, he penned The Middle Seat, The Wall Street Journal’s celebrated travel column, where he launched its highly regarded airline performance rankings.

McCartney was part of the Pulitzer Prize-winning team of journalists for its coverage of 9/11 and the author of four acclaimed books. His numerous accolades include the George Polk Award and SABEW’s “Best in Business” honors. Currently, he serves as an adjunct professor at Duke University and hosts Airlines Confidential, a globally recognized business podcast. He also leads Middle Seat LLC, a consultancy specializing in media training and aviation research.

Alex De Gunten

A seasoned aviation executive with a global perspective, Alex de Gunten joins the board with over 20 years of strategic leadership experience. As Business Development Officer at HEICO Aerospace, he has played a pivotal role in advancing aerospace innovation.

Previously, de Gunten served as Executive Director of the Latin American and Caribbean Air Transport Association (ALTA), fostering collaboration among regional airlines to address industry challenges. He also drove international expansion efforts as Vice President at LAN Chile and Canadian Airlines International. A multilingual leader fluent in English, Spanish, and French, de Gunten is a sought-after speaker and advisor to organizations such as ALTA and TravelX.

Strengthening Cirium’s Advisory Board

Chaired by Cirium CEO Jeremy Bowen, the board now comprises a powerhouse of aviation expertise, including former airline executive Willy Boulter, ACI World Director General Luis Felipe de Oliveira, and Atmosphere Research Group President Henry Harteveldt.

Board member, Mike Malik Cirium’s Chief Marketing Officer also serves as On-Time Committee Chairperson, and Lydia Webb, Cirium’s Marketing Director – Americas & Strategic Programs, is the Board Secretary.

This strengthened board equips Cirium to continue delivering unmatched insights and analytics to airlines, airports, and other stakeholders in the aviation industry.

About Cirium

Cirium® is the world’s most trusted source of aviation analytics. The company delivers powerful data and cutting-edge analytics to empower a wide spectrum of industry players. Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities with the clarity and intelligence they need to optimize their operations, make informed decisions, and accelerate revenue growth.

Cirium® is part of LexisNexis® Risk Solutions, a RELX business, which provides information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium® on LinkedIn or visit cirium.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204844057/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release

IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million

IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release

IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p

HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release

HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha

Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release

Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char

DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release

Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye